cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30327472.v1
title: First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis

description: Polatuzumab vedotin (Pola) is an anti-CD79b monoclonal antibody–drug conjugate that has shown remarkable efficacy and safety in diffuse large B-cell lymphoma (DLBCL) patients. Based on the results of the phase III POLARIX trial, it has been approved for first-line treatment of DLBCL. However, real-world studies are limited, particularly those assessing the efficacy differences between Pola-based regimens and traditional chemotherapy. This multicenter retrospective study analyzed clinical data from 64 newly diagnosed patients with advanced-stage, high-risk, or bulky DLBCL. Patients were categorized into the Pola plus chemotherapy (Pola) and traditional chemotherapy groups based on induction therapy. After excluding 6 patients who received fewer than four cycles of chemotherapy, 58 patients remained for efficacy analysis. The objective response rate after four cycles was 100% in the Pola group compared with 74.1% in the traditional chemotherapy group (<i>p</i> = 0.009). After a median follow-up of 13.5 months (range, 11.0–16.0 months), the median overall survival (OS), progression-free survival (PFS), and duration of response (DOR) in the Pola group were significantly longer than those in the traditional chemotherapy group (all <i>p</i> &lt; 0.05). Among patients with advanced disease, Pola plus chemotherapy was superior to traditional chemotherapy in terms of OS, PFS, and DOR (all <i>p</i> &lt; 0.05). For patients aged &gt;60 years with advanced disease, the Pola group had superior OS, PFS, and DOR (all <i>p</i> &lt; 0.05). Further subgroup survival analysis of patients receiving Pola-based therapy revealed that although the combination considerably improved PFS and DOR in advanced-stage patients, it did not overcome the poor prognosis associated with high P53 expression. Pola plus chemotherapy demonstrates superior efficacy and may prolong survival in patients with newly diagnosed advanced or high-risk DLBCL. However, it does not mitigate the unfavorable prognosis in patients with high P53 expression.
DOI: 10.6084/m9.figshare.29505892
title: Global, regional, and national burden of chronic respiratory diseases,1990–2021 and predictions to 2035: analysis of data from the global burden of disease study 2021

description: Chronic respiratory diseases (CRDs) have undergone significant epidemiological shifts in recent decades. This study comprehensively analyses the evolving global and regional burden of CRDs over the past 30 years and their attributable risk factors, aiming to identify key trends and inform effective prevention and control strategies. Using data from the Global Burden of Disease (GBD) 2021 database, this study examines trends in age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years rate (ASDR) for CRDs from 1990 to 2021, across global, regional, and national levels. Estimated annual percentage change (EAPC) was employed to quantify ASR trends over specified intervals. Additionally, Bayesian age-period-cohort (BAPC) modeling was utilized to depict and project CRD trends through 2035. In 2021, the global incidence of CRDs was 55.21 million (95% UI 48.68–64.56), predominantly comprising asthma (37.86 million; 95% UI 31.38–46.92) and chronic obstructive pulmonary disease (COPD) (16.90 million; 95% UI 15.47–18.34),  followed by interstitial lung disease (ILD) and pulmonary sarcoidosis (0.39 million; 95% UI 0.35–0.43) and pneumoconiosis (0.06 million; 95% UI 0.05–0.07). Since 1990, the age-standardized prevalence (ASPR) of CRDs has generally declined, except for ILD and pulmonary sarcoidosis, which increased by 8.74%. The global ASIR of CRDs is projected to continue declining, reaching 517.25 per 100,000 population by 2035, with ASMR of 39.21 per 100,000. Risk factor studies have shown that solid fuels burden remained higher among females in low-middle sociodemographic index (SDI) areas, while smoking-attributable burden predominated among males. This study characterizes the CRD burden across regions, ages, and sexes, identifying key risk factors to inform burden–reduction policies.
DOI: 10.6084/m9.figshare.29505892.v1
title: Global, regional, and national burden of chronic respiratory diseases,1990–2021 and predictions to 2035: analysis of data from the global burden of disease study 2021

description: Chronic respiratory diseases (CRDs) have undergone significant epidemiological shifts in recent decades. This study comprehensively analyses the evolving global and regional burden of CRDs over the past 30 years and their attributable risk factors, aiming to identify key trends and inform effective prevention and control strategies. Using data from the Global Burden of Disease (GBD) 2021 database, this study examines trends in age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years rate (ASDR) for CRDs from 1990 to 2021, across global, regional, and national levels. Estimated annual percentage change (EAPC) was employed to quantify ASR trends over specified intervals. Additionally, Bayesian age-period-cohort (BAPC) modeling was utilized to depict and project CRD trends through 2035. In 2021, the global incidence of CRDs was 55.21 million (95% UI 48.68–64.56), predominantly comprising asthma (37.86 million; 95% UI 31.38–46.92) and chronic obstructive pulmonary disease (COPD) (16.90 million; 95% UI 15.47–18.34),  followed by interstitial lung disease (ILD) and pulmonary sarcoidosis (0.39 million; 95% UI 0.35–0.43) and pneumoconiosis (0.06 million; 95% UI 0.05–0.07). Since 1990, the age-standardized prevalence (ASPR) of CRDs has generally declined, except for ILD and pulmonary sarcoidosis, which increased by 8.74%. The global ASIR of CRDs is projected to continue declining, reaching 517.25 per 100,000 population by 2035, with ASMR of 39.21 per 100,000. Risk factor studies have shown that solid fuels burden remained higher among females in low-middle sociodemographic index (SDI) areas, while smoking-attributable burden predominated among males. This study characterizes the CRD burden across regions, ages, and sexes, identifying key risk factors to inform burden–reduction policies.
DOI: 10.6084/m9.figshare.28028476
title: Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review

description: Poly ADP ribose polymerase (PARP) inhibitors, such as Olaparib (Lynparza<sup>®</sup>), are pivotal in treating certain cancers, particularly those linked to BReast CAncer gene (BRCA) mutations. Despite its established efficacy, Olaparib use is associated with various adverse events (AEs), notably haematologic toxicities, such as anaemia. This retrospective chart review study aimed to examine haematologic outcomes and associated factors in patients treated with Olaparib at a tertiary hospital in the UAE. We reviewed the medical charts of patients prescribed Olaparib and focused on haematologic indices at a baseline of 1-month, 3-month and 6-month follow-up periods. Data were analysed to determine the AEs frequency, transfusions need and potential associated patients’ clinical characteristics. This study included all patients who received Olaparib (<i>n</i> = 66). Most patients were females (<i>n</i> = 61; 92.4%) and the vast majority were non-smokers (97%) and free of hepatic disease. Themean age of the patients was 57.03-year-old (SD) = 12.06 years), and body mass index (BMI) was 28.16 (SD = 6.40) kg/m<sup>2</sup>. A high rate of anaemia (70.8%) was detected among the patients during their Olaparib therapy. Approximately, one-third of the patients developed neutropenia and thrombocytopenia. Transfusion was needed in almost half of the patients. Glomerular filtration rate (GFR) and neutropenia were significantly correlated with moderate-severe anaemia (OR = 0.097, 95% CI: 0.011–0.88, <i>p</i> value = .038) and (OR = 9.04, 95% CI: 1.024–79.78, <i>p</i> value = .048), respectively. Our findings highlight the side effects of Olaparib therapy in terms of haematology which could be avoided. Further studies are needed to better understand the therapeutic management of Olaparib and the mitigation of haematologic complications.
DOI: 10.6084/m9.figshare.28028476.v1
title: Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review

description: Poly ADP ribose polymerase (PARP) inhibitors, such as Olaparib (Lynparza<sup>®</sup>), are pivotal in treating certain cancers, particularly those linked to BReast CAncer gene (BRCA) mutations. Despite its established efficacy, Olaparib use is associated with various adverse events (AEs), notably haematologic toxicities, such as anaemia. This retrospective chart review study aimed to examine haematologic outcomes and associated factors in patients treated with Olaparib at a tertiary hospital in the UAE. We reviewed the medical charts of patients prescribed Olaparib and focused on haematologic indices at a baseline of 1-month, 3-month and 6-month follow-up periods. Data were analysed to determine the AEs frequency, transfusions need and potential associated patients’ clinical characteristics. This study included all patients who received Olaparib (<i>n</i> = 66). Most patients were females (<i>n</i> = 61; 92.4%) and the vast majority were non-smokers (97%) and free of hepatic disease. Themean age of the patients was 57.03-year-old (SD) = 12.06 years), and body mass index (BMI) was 28.16 (SD = 6.40) kg/m<sup>2</sup>. A high rate of anaemia (70.8%) was detected among the patients during their Olaparib therapy. Approximately, one-third of the patients developed neutropenia and thrombocytopenia. Transfusion was needed in almost half of the patients. Glomerular filtration rate (GFR) and neutropenia were significantly correlated with moderate-severe anaemia (OR = 0.097, 95% CI: 0.011–0.88, <i>p</i> value = .038) and (OR = 9.04, 95% CI: 1.024–79.78, <i>p</i> value = .048), respectively. Our findings highlight the side effects of Olaparib therapy in terms of haematology which could be avoided. Further studies are needed to better understand the therapeutic management of Olaparib and the mitigation of haematologic complications.
DOI: 10.6084/m9.figshare.28639902
title: Epidemiology of systemic sclerosis in the Asia-Pacific region: a systematic review and meta-analysis

description: The epidemiological profile of systemic sclerosis (SSc) in the population in Asia-Pacific countries might help in planning for improved future care and research direction. We aimed to estimate the pooled incidence and pooled prevalence of systemic sclerosis (SSc) in Asia-Pacific countries. We conducted and reported the systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement of 2020. Databases searched include PubMed, SCOPUS, CINAHL, and ProQuest, and hand searching, with a focus on publications from 1 January 2000 to 31 July 2023. A total of 456 records were identified from the searches, 10 articles were included for review: six reported the incidence of SSc; nine reported the prevalence of SSc. We noted considerable heterogeneity. Subgroup analyses categorized by the period of study before and after the launch of the 2013 ACR/EULAR Classification Criteria for SSc demonstrated that both incidence and prevalence of SSc were significantly different between subgroups. The incidence of SSc before and after the launch was 1.85 per 100,000 (4 studies, I<sup>2</sup> = 100%, 95%CI 0.53–6.40) and 9.61 per 100,000 (2 studies, I<sup>2</sup> = 100%, 95%CI 4.90–18.85), respectively. The prevalence of SSc before and after the launch was 6.47 per 100,000 (6 studies, I<sup>2</sup> = 97%, 95%CI 5.09–8.21) and 18.48 per 100,000 (3 studies, I<sup>2</sup> = 100%, 95%CI 7.19–47.50), respectively. The epidemiology of SSc varied widely across the Asia-Pacific region depending on the study methodology and study period. The incidence of SSc in the Asia-Pacific region was estimated to be higher after the launch of the new classification criteria. The incidence and prevalence of systemic sclerosis (SSc) vary widely across the Asia-Pacific region, influenced by differences in study methodologies. The incidence of SSc in the Asia-Pacific has risen following the implementation of the classification criteria.
DOI: 10.6084/m9.figshare.28639902.v1
title: Epidemiology of systemic sclerosis in the Asia-Pacific region: a systematic review and meta-analysis

description: The epidemiological profile of systemic sclerosis (SSc) in the population in Asia-Pacific countries might help in planning for improved future care and research direction. We aimed to estimate the pooled incidence and pooled prevalence of systemic sclerosis (SSc) in Asia-Pacific countries. We conducted and reported the systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement of 2020. Databases searched include PubMed, SCOPUS, CINAHL, and ProQuest, and hand searching, with a focus on publications from 1 January 2000 to 31 July 2023. A total of 456 records were identified from the searches, 10 articles were included for review: six reported the incidence of SSc; nine reported the prevalence of SSc. We noted considerable heterogeneity. Subgroup analyses categorized by the period of study before and after the launch of the 2013 ACR/EULAR Classification Criteria for SSc demonstrated that both incidence and prevalence of SSc were significantly different between subgroups. The incidence of SSc before and after the launch was 1.85 per 100,000 (4 studies, I<sup>2</sup> = 100%, 95%CI 0.53–6.40) and 9.61 per 100,000 (2 studies, I<sup>2</sup> = 100%, 95%CI 4.90–18.85), respectively. The prevalence of SSc before and after the launch was 6.47 per 100,000 (6 studies, I<sup>2</sup> = 97%, 95%CI 5.09–8.21) and 18.48 per 100,000 (3 studies, I<sup>2</sup> = 100%, 95%CI 7.19–47.50), respectively. The epidemiology of SSc varied widely across the Asia-Pacific region depending on the study methodology and study period. The incidence of SSc in the Asia-Pacific region was estimated to be higher after the launch of the new classification criteria. The incidence and prevalence of systemic sclerosis (SSc) vary widely across the Asia-Pacific region, influenced by differences in study methodologies. The incidence of SSc in the Asia-Pacific has risen following the implementation of the classification criteria.
DOI: 10.6084/m9.figshare.29665881
title: Early childhood trauma and its long-term impact on cognitive and emotional development: a systematic review and meta-analysis

description: Childhood trauma has profound, long-term effects on cognitive and emotional development. This systematic review and meta-analysis sought to synthesis the evidence around the long-term impact of human childhood trauma on domains of cognition and emotion in order to inform interventions and public health strategies. We systematically reviewed 465 studies from PubMed, Cochrane Library, and Google Scholar, 9 studies were included after duplicates were removed and inclusion and exclusion criteria were applied, and all 9 studies were aimed at low-income people in the United States. Data on study design, trauma types, and cognitive/emotional outcomes were extracted. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk of Bias Tool (RoB 2). Random-effects meta-analysis and subgroup analyses (processing speed, attention, working memory, emotion regulation, executive function) were conducted using R software. Childhood trauma was associated with significant deficits in: Attention (SMD = 2.37, 95% CI: [5.75, 10.50]) Working memory (SMD = 3.55, 95% CI: [2.18, 9.28]) Emotion regulation (SMD = 1.25, 95% CI: [1.12, 3.62]) Executive function (SMD = 1.61, 95% CI: [0.06, 3.28]) Processing speed showed smaller deficits (SMD = −0.48, 95% CI: [−1.91, 0.94]). High heterogeneity (I<sup>2</sup>: 77–98%) reflected variability in trauma types and assessments. The pooled effect size (SMD = 1.57, 95% CI: [−0.12, 3.26]) highlighted trauma’s pervasive impact. Childhood trauma disproportionately impairs attention and working memory. These findings, however, point to the importance of early screening, trauma-informed care and targeted interventions to ameliorate the long-term consequences of trauma, even with high heterogeneity. Methodological variability should be addressed to inform prevention and treatment strategies in future research, as well as resilience factors explored.
DOI: 10.6084/m9.figshare.29665881.v1
title: Early childhood trauma and its long-term impact on cognitive and emotional development: a systematic review and meta-analysis

description: Childhood trauma has profound, long-term effects on cognitive and emotional development. This systematic review and meta-analysis sought to synthesis the evidence around the long-term impact of human childhood trauma on domains of cognition and emotion in order to inform interventions and public health strategies. We systematically reviewed 465 studies from PubMed, Cochrane Library, and Google Scholar, 9 studies were included after duplicates were removed and inclusion and exclusion criteria were applied, and all 9 studies were aimed at low-income people in the United States. Data on study design, trauma types, and cognitive/emotional outcomes were extracted. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk of Bias Tool (RoB 2). Random-effects meta-analysis and subgroup analyses (processing speed, attention, working memory, emotion regulation, executive function) were conducted using R software. Childhood trauma was associated with significant deficits in: Attention (SMD = 2.37, 95% CI: [5.75, 10.50]) Working memory (SMD = 3.55, 95% CI: [2.18, 9.28]) Emotion regulation (SMD = 1.25, 95% CI: [1.12, 3.62]) Executive function (SMD = 1.61, 95% CI: [0.06, 3.28]) Processing speed showed smaller deficits (SMD = −0.48, 95% CI: [−1.91, 0.94]). High heterogeneity (I<sup>2</sup>: 77–98%) reflected variability in trauma types and assessments. The pooled effect size (SMD = 1.57, 95% CI: [−0.12, 3.26]) highlighted trauma’s pervasive impact. Childhood trauma disproportionately impairs attention and working memory. These findings, however, point to the importance of early screening, trauma-informed care and targeted interventions to ameliorate the long-term consequences of trauma, even with high heterogeneity. Methodological variability should be addressed to inform prevention and treatment strategies in future research, as well as resilience factors explored.
DOI: 10.6084/m9.figshare.30900278
title: Effectiveness of different antibiotic lock solutions on catheter-related infections of hemodialysis patients: a systematic review and meta-analysis

description: Antibiotic lock therapy (ALT) delivers high‐concentration antimicrobials into catheter lumens and has been proposed to prevent infections in hemodialysis (HD) patients. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) and quasi-experimental studies comparing ALT with non-antibiotic or no-lock solutions in adults on HD. Six databases (PubMed, Embase, Scopus, Web of Science, Cochrane CENTRAL, CINAHL) were searched through 27 June 2025, identifying 17 studies involving 3,482 catheters. Two independent reviewers extracted data and assessed bias using the Cochrane RoB 2. Random‐effects models yielded pooled risk ratios (RR) and incidence rate ratios (IRR) with 95% confidence intervals (CI). ALT reduced catheter‐related bloodstream infections (CRBSI) by 63% (RR= 0.37, 95% CI: 0.29–0.49; <i>p</i> &lt; 0.001). Overall, catheter‐related infection incidence rates fell (IRR 0.24, 95% CI: 0.15–0.38; <i>p</i> &lt; 0.001) despite potential for publication bias (Egger’s <i>p</i> = 0.003). No significant effects appeared for exit‐site infections (ESI) (RR= 0.90; <i>p</i> = 0.59), thrombosis (RR= 0.73; <i>p</i> = 0.23), or mortality (RR= 0.58; <i>p</i> = 0.09). GRADE assessed the evidence for CRBSI as having high certainty, while evidence for ESI was moderate, and evidence for other outcomes ranged from low to very low. ALT significantly reduces CRBSI in HD patients and can be considered as a preventive adjunct.
DOI: 10.6084/m9.figshare.30900278.v1
title: Effectiveness of different antibiotic lock solutions on catheter-related infections of hemodialysis patients: a systematic review and meta-analysis

description: Antibiotic lock therapy (ALT) delivers high‐concentration antimicrobials into catheter lumens and has been proposed to prevent infections in hemodialysis (HD) patients. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) and quasi-experimental studies comparing ALT with non-antibiotic or no-lock solutions in adults on HD. Six databases (PubMed, Embase, Scopus, Web of Science, Cochrane CENTRAL, CINAHL) were searched through 27 June 2025, identifying 17 studies involving 3,482 catheters. Two independent reviewers extracted data and assessed bias using the Cochrane RoB 2. Random‐effects models yielded pooled risk ratios (RR) and incidence rate ratios (IRR) with 95% confidence intervals (CI). ALT reduced catheter‐related bloodstream infections (CRBSI) by 63% (RR= 0.37, 95% CI: 0.29–0.49; <i>p</i> &lt; 0.001). Overall, catheter‐related infection incidence rates fell (IRR 0.24, 95% CI: 0.15–0.38; <i>p</i> &lt; 0.001) despite potential for publication bias (Egger’s <i>p</i> = 0.003). No significant effects appeared for exit‐site infections (ESI) (RR= 0.90; <i>p</i> = 0.59), thrombosis (RR= 0.73; <i>p</i> = 0.23), or mortality (RR= 0.58; <i>p</i> = 0.09). GRADE assessed the evidence for CRBSI as having high certainty, while evidence for ESI was moderate, and evidence for other outcomes ranged from low to very low. ALT significantly reduces CRBSI in HD patients and can be considered as a preventive adjunct.